Business Context and Reporting Period
Company: Eli Lilly and Company
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Eli Lilly is a global pharmaceutical company operating primarily in one significant business segment: pharmaceutical products. It also maintains an animal health segment, which is not material to financial statements. The company discovers, develops, manufactures, and sells products in approximately 135 countries. Key therapeutic areas include neurosciences (e.g., Zyprexa, Cymbalta), endocrinology (e.g., Humalog, Byetta), oncology (e.g., Gemzar, Alimta), and cardiovascular (e.g., Cialis).
Key Financial Metrics (2007)
| Metric | 2007 Value | 2006 Value | Change |
|---|---|---|---|
| Net Sales | $18,633.5 million | $15,691.0 million | +19% |
| Net Income | $2,953.0 million | $2,662.7 million | +11% |
| Earnings Per Share (Diluted) | $2.71 | $2.45 | +11% |
| Gross Margin | 77.2% | 77.4% | -0.2 pts |
| Operating Expenses | $9,581.8 million | $8,019.1 million | +19% |
| Research & Development | $3,486.7 million | $3,129.3 million | +11% |
| Cash Flow from Operations | $5,154.5 million | $3,975.9 million | +30% |
| Total Debt | $5,012.3 million | $3,714.6 million | +35% |
| Cash & Equivalents | $3,220.5 million | $3,109.3 million | +4% |
Note: Operating expenses include R&D, Marketing/Selling/Admin, Acquired IPR&D, and Asset Impairments.
Material Changes vs. Prior Period
- Acquisition of ICOS: The most significant driver of 2007 results was the acquisition of ICOS Corporation in January 2007 for approximately $2.3 billion. This brought full ownership of the erectile dysfunction drug Cialis, which contributed $1.14 billion in net sales in 2007 (compared to $215.8 million in 2006 when only exclusive territories were reported).
- Product Growth: Sales of Cymbalta increased 60% to $2.1 billion, driven by strong demand. Zyprexa sales grew 9% to $4.76 billion. Alimta sales rose 40% to $854 million.
- Special Charges: The company incurred significant non-recurring charges in 2007, including:
- Acquired In-Process R&D (IPR&D): $745.6 million related to ICOS, Hypnion, Ivy, and licensing agreements.
- Asset Impairments & Restructuring: $302.5 million (down from $945.2 million in 2006).
- Product Liability: $111.9 million net pretax charge related to Zyprexa settlements and reserves.
- Debt Increase: Total debt increased by $1.29 billion, primarily due to $2.5 billion in debt issued to finance the ICOS acquisition.
Guidance, Outlook, and Risks
2008 Guidance
- Earnings Per Share: Expected to be in the range of $3.80 to $3.95.
- Sales Growth: Expected to grow in the mid-to-high single digits, driven by Cymbalta, Cialis, Byetta, Alimta, and Humalog.
- Expenses: Operating expenses expected to grow in the mid-single digits; R&D expected to grow in the high-single to low-double digits.
- Capital Expenditures: Expected to be approximately $1.1 billion.
Key Risks and Contingencies
- Zyprexa Litigation: The company faces extensive product liability litigation regarding Zyprexa (alleged links to diabetes). While settlements covering ~31,200 claims have been reached, approximately 1,235 claims remain. Aggregate net pretax charges since 2005 total $1.61 billion. The company is largely self-insured for future product liability losses.
- Patent Expirations: Generic competition is a material risk. Zyprexa patents expire in 2011 in the U.S., but generic versions have already entered markets in Canada and Germany following adverse court rulings. Other key products (Cymbalta, Gemzar, Humalog) face patent expirations between 2010 and 2017.
- Government Investigations: The company is subject to investigations by the U.S. Attorney for the Eastern District of Pennsylvania and various state attorneys general regarding marketing and promotional practices for Zyprexa, Prozac, and other products. Outcomes could result in fines, penalties, or exclusion from federal healthcare programs.
- Regulatory & Pricing: Increasing government price controls and cost-containment measures (e.g., Medicare Part D, Medicaid rebates) continue to pressure pricing and reimbursement.
Investor Verification Checklist
- Zyprexa Exposure: Verify the status of remaining Zyprexa product liability claims and the adequacy of current reserves against potential future settlements or judgments.
- Patent Litigation Outcomes: Monitor the status of patent challenges for Zyprexa (outside the U.S.), Evista, Gemzar, and Strattera, as generic entry could materially impact future revenue.
- Government Investigations: Track the resolution of federal and state investigations into marketing practices, which could lead to significant financial penalties.
- Acquisition Integration: Assess the realization of synergies and operational efficiencies from the ICOS acquisition, particularly regarding Cialis sales growth.
- 2008 Guidance Achievement: Compare actual 2008 results against the provided EPS guidance of $3.80–$3.95, noting the impact of the anticipated $87 million BioMS IPR&D charge in Q1 2008.